

Form 990

Return of Organization Exempt From Income Tax
Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except black lung benefit trust or private foundation)

OMB No. 1545-0047

2002

Open to Public Inspection

Department of the Treasury Internal Revenue Service

The organization may have to use a copy of this return to satisfy state reporting requirements

A For the 2002 calendar year, or tax year beginning, and ending

B Check if applicable: Address change, Name change, Initial return, Final return, Amended return, Application pending. C Name of organization: LIFE EXTENSION FOUNDATION, INC. D Employer ID number: 59-1746396. E Telephone number: 954-985-8600. F Accounting method: Accrual.

Section 501(c)(3) organizations and 4947(a)(1) nonexempt charitable trusts must attach a completed Schedule A (Form 990 or 990-EZ)

G Web site WWW.LEF.ORG

J Organization type (check only one) 501(c)(3) < (insert no) 4947(a)(1) or 527

K Check here if the organization's gross receipts are normally not more than \$25,000. The organization need not file a return with the IRS, but if the organization received a Form 990 Package in the mail, it should file a return without financial data. Some states require a complete return.

H and I are not applicable to section 527 organizations. H(a) Is this a group return for affiliates? H(b) If "Yes" enter no. of affiliates. H(c) Are all affiliates included? H(d) Is this a separate return filed by an organization covered by a group ruling? I Enter 4-digit GEN. M Check if the organization is not required to attach Sch B (Form 990, 990-EZ, or 990-PF).

L Gross receipts Add lines 6b, 8b, 9b, and 10b to line 12 9,141,487

Part I Revenue, Expenses, and Changes in Net Assets or Fund Balances (See page 17 of the instructions)

SCANNED DEC 03 2003

Table with 21 rows and 3 columns: Description, Amount, and Total. Includes sections for Revenue (lines 1-12), Expenses (lines 13-17), and Net Assets (lines 18-21). Total revenue is 9,059,299 and total expenses is 4,610,848.

**Part II Statement of Functional Expenses** All organizations must complete column (A). Columns (B), (C), and (D) are required for section 501(c)(3) and (4) organizations and section 4947(a)(1) nonexempt charitable trusts but optional for others. (See page 21 of the instructions.)

Do not include amounts reported on line 6b, 8b, 9b, 10b, or 16 of Part I		(A) Total	(B) Program services	(C) Management and general	(D) Fundraising
22	Grants and allocations (attach schedule) (cash \$ <u>3,881,631</u> non-cash \$ <u>SEE NOTE C</u> )	22 3,881,631	3,881,631		
23	Specific assistance to individuals	23			
24	Benefits paid to or for members	24			
25	Compensation of officers, directors, etc	25			
26	Other salaries and wages	26			
27	Pension plan contributions	27			
28	Other employee benefits	28			
29	Payroll taxes	29			
30	Professional fundraising fees	30			
31	Accounting fees	31 200		200	
32	Legal fees	32 378,573		378,573	
33	Supplies	33			
34	Telephone	34			
35	Postage and shipping	35 69,369		69,369	
36	Occupancy	36			
37	Equipment rental and maintenance	37			
38	Printing and publications	38 127,600		127,600	
39	Travel	39			
40	Conferences, conventions, and meetings	40			
41	Interest	41 1,772		1,772	
42	Depreciation, depletion, etc (attach schedule)	42 26,667		26,667	
43	Other expenses not covered above (itemize) a	43a			
	b SEE STATEMENT	43b 125,036		125,036	
	c	43c			
	d	43d			
	e	43e			
44	<b>Total functional expenses</b> (add lines 22 - 43) Organizations completing columns (B)-(D), carry these totals to lines 13-15	44 4,610,848	3,881,631	729,217	0

**Joint Costs** Check  if you are following SOP 98-2  
 Are any joint costs from a combined educational campaign and fundraising solicitation reported in (B) Program services?  Yes  No  
 If "Yes," enter (i) the aggregate amount of these joint costs \$ \_\_\_\_\_, (ii) the amount allocated to Program services \$ \_\_\_\_\_,  
 (iii) the amount allocated to Management and general \$ \_\_\_\_\_, and (iv) the amount allocated to Fundraising \$ \_\_\_\_\_

**Part III Statement of Program Service Accomplishments** (See page 24 of the instructions)

What is the organization's primary exempt purpose?	Program Service Expenses (Required for 501(c)(3) & (4) orgs. & 4947(a)(1) trusts, but optional for others.)
SEE NOTE D	
a SEE NOTE D	
(Grants and allocations \$ _____)	3,881,631
b	
(Grants and allocations \$ _____)	
c	
(Grants and allocations \$ _____)	
d	
(Grants and allocations \$ _____)	
e Other program services (attach schedule)	(Grants and allocations \$ _____)
<b>f Total of Program Service Expenses</b> (should equal line 44, column (B), Program services)	<b>3,881,631</b>

**Part IV Balance Sheets** (See page 24 of the instructions)

Note: Where required, attached schedules and amounts within the description column should be for end-of-year amounts only		(A) Beginning of year		(B) End of year
45	Cash - non-interest-bearing	3,837,115	45	2,025,500
46	Savings and temporary cash investments		46	
47a	Accounts receivable			
b	Less allowance for doubtful accounts	5,270,622	47c	
48a	Pledges receivable			
b	Less allowance for doubtful accounts		48c	
49	Grants receivable		49	
50	Receivables from officers, directors, trustees, and key employees (attach schedule)		50	
51a	Other notes and loans receivable (attach schedule) SEE NOTE E	15,326,991		
b	Less allowance for doubtful accounts	6,641,880	51c	15,326,991
52	Inventories for sale or use		52	
53	Prepaid expenses and deferred charges		53	
54	Investments-securities SEE NOTE F <input type="checkbox"/> Cost <input checked="" type="checkbox"/> FMV	2,520,103	54	5,719,292
55a	Investments-land, buildings, and equipment basis	417,254		
b	Less accumulated depreciation (attach schedule)	58,841	55c	358,413
56	Investments-other (attach schedule) SEE NOTE G	323,764	56	323,764
57a	Land, buildings, and equipment basis			
b	Less accumulated depreciation (attach schedule)		57c	
58	Other assets (describe )	266,665	58	239,998
59	<b>Total assets</b> (add lines 45 through 58) (must equal line 74)	19,229,260	59	23,993,958
60	Accounts payable and accrued expenses		60	
61	Grants payable		61	
62	Deferred revenue		62	
63	Loans from officers, directors, trustees, and key employees (attach schedule)		63	
64a	Tax-exempt bond liabilities (attach schedule)		64a	
b	Mortgages and other notes payable (attach schedule)		64b	
65	Other liabilities (describe )	3,136	65	5,786
66	<b>Total liabilities</b> (add lines 60 through 65)	3,136	66	5,786
Organizations that follow SFAS 117, check here <input checked="" type="checkbox"/> and complete lines 67 through 69 and lines 73 and 74				
67	Unrestricted	19,226,124	67	23,988,172
68	Temporarily restricted		68	
69	Permanently restricted		69	
Organizations that do not follow SFAS 117, check here <input type="checkbox"/> and complete lines 70 through 74				
70	Capital stock, trust principal, or current funds		70	
71	Paid-in or capital surplus, or land, building, and equipment fund		71	
72	Retained earnings, endowment, accumulated income, or other funds		72	
73	<b>Total net assets or fund balances</b> (add lines 67 through 69 or lines 70 through 72, column (A) must equal line 19, column (B) must equal line 21)	19,226,124	73	23,988,172
74	<b>Total liabilities and net assets / fund balances</b> (add lines 66 and 73)	19,229,260	74	23,993,958

Form 990 is available for public inspection and, for some people, serves as the primary or sole source of information about a particular organization. How the public perceives an organization in such cases may be determined by the information presented on its return. Therefore, please make sure the return is complete and accurate and fully describes, in Part III, the organization's programs and accomplishments.

**Part IV-A Reconciliation of Revenue per Audited Financial Statements with Revenue per Return (See page 26 of the instructions)**

**Part IV-B Reconciliation of Expenses per Audited Financial Statements with Expenses per Return**

N/A

a	Total revenue, gains, & other support per audited financial statements	a
b	Amounts included on line a but not on line 12, Form 990	
	(1) Net unrealized gains on investments \$	
	(2) Donated services and use of facilities \$	
	(3) Recoveries of prior year grants \$	
	(4) Other (specify)	
	\$	
	Add amounts on lines (1) through (4)	b
c	Line a minus line b	c
d	Amounts included on line 12, Form 990 but not on line a	
	(1) Investment expenses not included on line 6b, Form 990 \$	
	(2) Other (specify)	
	\$	
	Add amounts on lines (1) and (2)	d
e	Total revenue per line 12, Form 990 (line c plus line d)	e

N/A

a	Total expenses and losses per audited financial statements	a
b	Amounts included on line a but not on line 17, Form 990	
	(1) Donated services and use of facilities \$	
	(2) Prior year adjustments reported on line 20, Form 990 \$	
	(3) Losses reported on line 20, Form 990 \$	
	(4) Other (specify)	
	\$	
	Add amounts on lines (1) through (4)	b
c	Line a minus line b	c
d	Amounts included on line 17, Form 990 but not on line a	
	(1) Investment expenses not included on line 6b, Form 990 \$	
	(2) Other (specify)	
	\$	
	Add amounts on lines (1) and (2)	d
e	Total expenses per line 17, Form 990 (line c plus line d)	e

**Part V List of Officers, Directors, Trustees, and Key Employees (List each one even if not compensated, see page 26 of the instructions)**

(A) Name and address	(B) Title and average hours per week devoted to position	(C) Compensation (if not paid, enter -0-)	(D) Contrib to employee benefit plans & deferred compensation	(E) Expense account and other allowances
TINA EYCHISON 1100 COMM. BLVD, FT LAUDERDALE, FL	PRES./DIR. 5	0	0	0
WILLIAM FALCON 1100 COMM. BLVD, FT. LAUDERDALE, FL	DIRECTOR 5	0	0	0
SAUL KENT 1100 COMM. BLVD, FT. LAUDERDALE, FL	DIRECTOR 5	0	0	0
JIM HALPERN 1100 COMM. BLVD, FT. LAUDERDALE, FL	DIRECTOR 5	0	0	0
KEVIN BROWN 1100 COMM. BLVD, FT. LAUDERDALE, FL	DIRECTOR 5	0	0	0
PAUL GILNER 1100 COMM. BLVD, FT. LAUDERDALE, FL	ASS'T TREAS 5	0	0	0

75 Did any officer, director, trustee, or key employee receive aggregate compensation of more than \$100,000 from your organization and all related organizations, of which more than \$10,000 was provided by the related organizations? If "Yes," attach schedule-see page 26 of the instructions

Yes  No

Part VI Other Information (See page 27 of the instructions)

		Yes	No
76	Did the organization engage in any activity not previously reported to the IRS? If "Yes," attach a detailed description of each activity		X
77	Were any changes made in the organizing or governing documents but not reported to the IRS? If "Yes," attach a conformed copy of the changes		X
78a	Did the organization have unrelated business gross inc of \$1,000 or more during the year covered by this return?		X
b	If "Yes," has it filed a tax return on Form 990-T for this year?	N/A	
79	Was there a liquidation, dissolution, termination, or substantial contraction during the year? If "Yes," attach a statement		X
80a	Is the organization related (other than by association with a statewide or nationwide organization) through common membership, governing bodies, trustees, officers, etc., to any other exempt or nonexempt organization?		X
b	If "Yes," enter the name of the organization <input type="checkbox"/> and check whether it is <input type="checkbox"/> exempt or <input type="checkbox"/> nonexempt		
81a	Enter direct or indirect political expenditures See line 81 instr	81a	
b	Did the organization file Form 1120-POL for this year?	N/A	
82a	Did the organization receive donated services or the use of materials, equipment, or facilities at no charge or at substantially less than fair rental value?	82a	X
b	If "Yes," you may indicate the value of these items here Do not include this amount as revenue in Part I or as an expense in Part II (See instructions in Part III) SEE NOTE J	82b	
83a	Did the organization comply with the public inspection requirements for returns and exemption applications?	83a	X
b	Did the organization comply with the disclosure requirements relating to quid pro quo contributions? SEE NOTE H	N/A	
84a	Did the organization solicit any contributions or gifts that were not tax deductible?	84a	X
b	If "Yes," did the organization include with every solicitation an express statement that such contributions or gifts were not tax deductible?	N/A	
85	501(c)(4), (5), or (6) organizations a Were substantially all dues nondeductible by members?	N/A	
b	Did the organization make only in-house lobbying expenditures of \$2,000 or less? If "Yes" was answered to either 85a or 85b, do not complete 85c through 85h below unless the organization received a waiver for proxy tax owed for the prior year	N/A	
c	Dues, assessments, and similar amounts from members	85c	
d	Section 162(e) lobbying and political expenditures	85d	
e	Aggregate nondeductible amount of section 6033(e)(1)(A) dues notices	85e	
f	Taxable amount of lobbying and political expenditures (line 85d less 85e)	85f	
g	Does the organization elect to pay the section 6033(e) tax on the amount in 85f?	N/A	
h	If section 6033(e)(1)(A) dues notices were sent, does the organization agree to add the amount in 85f to its reasonable estimate of dues allocable to nondeductible lobbying and political expenditures for the following tax year?	N/A	
86	501(c)(7) orgs Enter a Initiation fees and capital contributions included on line 12	86a	N/A
b	Gross receipts, included on line 12, for public use of club facilities	86b	N/A
87	501(c)(12) orgs Enter a Gross income from members or shareholders	87a	N/A
b	Gross income from other sources (Do not net amounts due or paid to other sources against amounts due or received from them)	87b	N/A
88	At any time during the year, did the organization own a 50% or greater interest in a taxable corporation or partnership, or an entity disregarded as separate from the organization under Regulations sections 301.7701-2 and 301.7701-3? If "Yes," complete Part IX SEE NOTE K	88	X
89a	501(c)(3) organizations Enter Amount of tax imposed on the organization during the year under section 4911 <u>0</u> , section 4912 <u>0</u> , section 4955 <u>0</u>		
b	501(c)(3) and 501(c)(4) orgs Did the organization engage in any section 4958 excess benefit transaction during the year or did it become aware of an excess benefit transaction from a prior year? If "Yes," attach a statement explaining each transaction	89b	X
c	Enter Amount of tax imposed on the organization managers or disqualified persons during the year under sections 4912, 4955, and 4958	<u>0</u>	
d	Enter Amount of tax on line 89c, above, reimbursed by the organization	<u>0</u>	
90a	List the states with which a copy of this return is filed <u>FL</u>		
b	Number of employees employed in the pay period that includes March 12, 2002 (See instructions)	90b	<u>0</u>
91	The books are in care of <u>BERNARD A. SINGER PA</u> Telephone no <u>954-985-8600</u> Located at <u>3107 STIRLING RD. #105; FT. LAUD., FL</u> ZIP + 4 <u>33312</u>		
92	Section 4947(a)(1) nonexempt charitable trusts filing Form 990 in lieu of Form 1041- Check here and enter the amount of tax-exempt interest received or accrued during the tax year <u>92</u>		

**Part VII Analysis of Income-Producing Activities (See page 31 of the instructions)**

	Unrelated business income		Excluded by sec 512, 513 or 514		(E) Related or exempt function income
	(A) Business code	(B) Amount	(C) Exclusion code	(D) Amount	
<b>Note</b> Enter gross amounts unless otherwise indicated					
93 Program service revenue					
a _____					
b _____					
c _____					
d _____					
e _____					
f Medicare/Medicaid payments					
g Fees and contracts from government agencies					
94 Membership dues and assessments					4,726,777
95 Interest on savings and temporary cash investments			13	1,793,261	
96 Dividends and interest from securities			13	21,641	
97 Net rental income or (loss) from real estate					
a debt-financed property					
b not debt-financed property			13	-4,432	
98 Net rental income or (loss) from personal property					
99 Other investment income			0	0	
100 Gain or (loss) from sales of assets other than inventory				-37,199	
101 Net income or (loss) from special events					
102 Gross profit or (loss) from sales of inventory					
103 Other revenue					
a _____					
b <u>ROYALTY INCOME</u>			13	2,501,857	
c _____					
d _____					
e _____					
104 Subtotal (add columns (B), (D), and (E))			0	4,275,128	4,726,777
105 Total (add line 104, columns (B), (D), and (E))					9,001,905

**Note** Line 105 plus line 1d, Part I, should equal the amount on line 12, Part I

**Part VIII Relationship of Activities to the Accomplishment of Exempt Purposes (See page 32 of the instructions)**

Line No	Explain how each activity for which income is reported in column (E) of Part VII contributed importantly to the accomplishment of the organization's exempt purposes (other than by providing funds for such purposes)
94	TO SUPPORT SCIENTIFIC AND MEDICAL RESEARCH AND GATHER AND PUBLISH INFORMATION RELATING TO PREVENTING DEGENERATIVE DISEASE.

**Part IX Information Regarding Taxable Subsidiaries and Disregarded Entities (See page 32 of the instructions)**

(A) Name, address, and EIN of corporation, partnership, or disregarded entity	(B) Percentage of ownership interest	(C) Nature of activities	(D) Total income	(E) End-of-year assets
SEE NOTE K	%			
	%			
	%			
	%			

**Part X Information Regarding Transfers Associated with Personal Benefit Contracts (See page 33 of the instructions)**

- (a) Did the organization during the year receive any funds, directly or indirectly, to pay premiums on a personal benefit contract?  Yes  No
  - (b) Did the organization, during the year, pay premiums, directly or indirectly, on a personal benefit contract?  Yes  No
- Note** If "Yes" to (b), file Form 8870 and Form 4720 (see instructions)

**Please Sign Here**

Under penalties of perjury I declare that I have examined this return including schedules and believe it is true, correct, and complete. Declaration of preparer (other than officer) if self-employed, address, and ZIP + 4

Signature of officer: *[Signature]*  
Type or print name and title: *PAUL COOPER ASSISTANT*

**Paid Preparer's Use Only**

Preparer's signature: *[Signature]*  
Firm's name (or yours if self-employed), address, and ZIP + 4: **BURTON & COMPANY, 4310 SHERIDAN ST., HOLLYWOOD, FL 330**

**SCHEDULE A**  
(Form 990 or 990-EZ)

**Organization Exempt Under Section 501(c)(3)**  
(Except Private Foundation) and Section 501(e), 501(f), 501(k),  
501(n), or Section 4947(a)(1) Nonexempt Charitable Trust  
**Supplementary Information-(See separate instructions.)**

OMB No 1545-0047

**2002**

Department of the Treasury  
Internal Revenue Service

▶ **MUST be completed by the above organizations and attached to their Form 990 or 990-EZ**

Name of the organization

Employer identification number

LIFE EXTENSION FOUNDATION, INC

59-1746396

**Part I Compensation of the Five Highest Paid Employees Other Than Officers, Directors, and Trustees**  
(See page 1 of the instructions List each one If there are none, enter "None")

(a) Name and address of each employee paid more than \$50,000	(b) Title and average hours per week devoted to position	(c) Compensation	(d) Contributions to employee ben plans & deferred compensation	(e) Expense account and other allowances
NONE				
Total number of other employees paid over \$50,000				

**Part II Compensation of the Five Highest Paid Independent Contractors for Professional Services**  
(See page 2 of the instr List each one (whether individuals or firms) If there are none, enter "None")

(a) Name and address of each independent contractor paid more than \$ 50,000	(b) Type of service	(c) Compensation
BERNARD A. SINGER, PA 3107 STRLG RD.; #105; FT. LAUD., FL33312	LEGAL/ACCTG	215,658
POWELL, GOLDSTEIN, FRAZER&MURPHY, LLP 1001 PENN. AV. NW; 6FLOOR; WASH, DC20004	LEGAL	162,524
Total number of others receiving over \$50,000 for professional services	0	

For Paperwork Reduction Act Notice, see the Instructions for Form 990 and Form 990-EZ

Schedule A (Form 990 or 990-EZ) 2002

**Part III Statements About Activities** (See page 2 of the instructions.)

	Yes	No
<b>1</b> During the year, has the organization attempted to influence national, state, or local legislation, including any attempt to influence public opinion on a legislative matter or referendum? If "Yes," enter the total expenses paid or incurred in connection with the lobbying activities <b>\$</b> <u>0</u> (Must equal amount on line 38, Part VI-A, or line I of Part VI-B) Organizations that made an election under section 501(h) by filing Form 5768 must complete Part VI-A. Other organizations checking "Yes," must complete Part VI-B AND attach a statement giving a detailed description of the lobbying activities.	X	
<b>2</b> During the year, has the organization, either directly or indirectly, engaged in any of the following acts with any substantial contributors, trustees, directors, officers, creators, key employees, or members of their families, or with any taxable organization with which any such person is affiliated as an officer, director, trustee, majority owner, or principal beneficiary? (If the answer to any question is "Yes," attach a detailed statement explaining the transactions.)		
<b>a</b> Sale, exchange, or leasing of property?		X
<b>b</b> Lending of money or other extension of credit?	X	
SEE NOTE E & NOTE I		
<b>c</b> Furnishing of goods, services, or facilities?		X
<b>d</b> Payment of compensation (or payment or reimbursement of exp. if more than \$1,000)?		X
<b>e</b> Transfer of any part of its income or assets?		X
<b>3</b> Does the organization make grants for scholarships, fellowships, student loans, etc.? (See Note below.)		X
<b>4</b> Do you have a section 403(b) annuity plan for your employees?		X
<b>Note</b> Attach a statement to explain how the organization determines that individuals or organizations receiving grants or loans from it in furtherance of its charitable programs "qualify" to receive payments.		

**Part IV Reason for Non-Private Foundation Status** (See pages 3 through 5 of the instructions.)

The organization is not a private foundation because it is (Please check only ONE applicable box.)

- 5  A church, convention of churches, or association of churches. Section 170(b)(1)(A)(i)
- 6  A school. Section 170(b)(1)(A)(ii) (Also complete Part V.)
- 7  A hospital or a cooperative hospital service organization. Section 170(b)(1)(A)(iii)
- 8  A Federal, state, or local government or governmental unit. Section 170(b)(1)(A)(v)
- 9  A medical research organization operated in conjunction with a hospital. Section 170(b)(1)(A)(iii) Enter the hospital's name, city, and state. ▶
- 10  An organization operated for the benefit of a college or university owned or operated by a governmental unit. Section 170(b)(1)(A)(iv) (Also complete the Support Schedule in Part IV-A.)
- 11a  An organization that normally receives a substantial part of its support from a governmental unit or from the general public. Section 170(b)(1)(A)(vi) (Also complete the Support Schedule in Part IV-A.) SEE NOTE L
- 11b  A community trust. Section 170(b)(1)(A)(vi) (Also complete the Support Schedule in Part IV-A.)
- 12  An organization that normally receives (1) more than 33 1/3% of its support from contributions, membership fees, and gross receipts from activities related to its charitable, etc., functions-subject to certain exceptions, and (2) no more than 33 1/3% of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975. See section 509(a)(2) (Also complete the Support Schedule in Part IV-A.)
- 13  An organization that is not controlled by any disqualified persons (other than foundation managers) and supports organizations described in (1) lines 5 through 12 above, or (2) section 501(c)(4), (5), or (6), if they meet the test of section 509(a)(2) (See section 509(a)(3).)

Provide the following information about the supported organizations (See page 5 of the instructions.)

(a) Name(s) of supported organization(s)	(b) Line number from above

- 14  An organization organized and operated to test for public safety. Section 509(a)(4) (See page 5 of the instructions.)



**Part IV-A Support Schedule** (Complete only if you checked a box on line 10, 11, or 12) Use cash method of accounting

**Note** You may use the worksheet in the instructions for converting from the accrual to the cash method of accounting

Calendar year (or fiscal year beginning in)	(a) 2001	(b) 2000	(c) 1999	(d) 1998	(e) Total
15 Gifts, grants, and contributions received (Do not include unusual grants See line 28)	4,225	10,000	6,000	13,616	33,841
16 Membership fees received	3,979,445	2,490,346	2,272,711	2,133,629	10,876,131
17 Gross receipts from admissions, merchandise sold or services performed, or furnishing of facilities in any activity that is related to the organization's charitable, etc. purpose					
18 Gross inc from int. dividends amounts received from pymt. on securities loans (section 512(a)(5)) rents, royalties, & unrelated busn taxable inc (less sec 511 taxes) from businesses acquired by the organization after June 30 1975	3,676,999	3,502,286	3,455,954	3,168,913	13,804,152
19 Net income from unrelated business activities not included in line 18					
20 Tax revn levied for the organization's ben & either paid to it or expended on its behalf					
21 The value of serv or fac <sup>y</sup> furnished to the org by a governmental unit without charge Do not incl the value of serv or fac generally furnished to the public without charge					
22 Other income Attach a schedule Do not include gain or (loss) from sale of cap assets					
23 Total of lines 15 through 22	7,660,669	6,002,632	5,734,665	5,316,158	24,714,124
24 Line 23 minus line 17	7,660,669	6,002,632	5,734,665	5,316,158	24,714,124
25 Enter 1% of line 23	76,607	60,026	57,347	53,162	
26 Organizations described on lines 10 or 11	a Enter 2% of amount in column (e), line 24				26a 494,282
	b Prepare a list for your records to show the name of and amount contributed by each person (other than a governmental unit or publicly supported organization) whose total gifts for 1998 through 2001 exceeded the amount shown in line 26a Do not file this list with your return Enter the total of all these excess amounts				26b
	c Total support for section 509(a)(1) test. Enter line 24, column (e)				26c 24,714,124
	d Add Amounts from column (e) for lines 18 <u>13,804,152</u> 19 _____ 22 _____ 26b _____				26d 13,804,152
	e Public support (line 26c minus line 26d total)				26e 10,909,972
	f Public support percentage (line 26e (numerator) divided by line 26c (denominator))				26f 44.1447%
27 Organizations described on line 12	a For amounts included in lines 15, 16, and 17 that were received from a "disqualified person," prepare a list for your records to show the name of, and total amounts received in each year from, each "disqualified person" Do not file this list with your return Enter the sum of such amounts for each year				N/A
	(2001)	(2000)	(1999)	(1998)	
	b For any amount included in line 17 that was received from each person (other than "disqualified persons"), prepare a list for your records to show the name of, and amount received for each year, that was more than the larger of (1) the amount on line 25 for the year or (2) \$5,000 (Include in the list organizations described in lines 5 through 11, as well as individuals) Do not file this list with your return After computing the difference between the amount received and the larger amount described in (1) or (2), enter the sum of these differences (the excess amounts) for each year				N/A
	(2001)	(2000)	(1999)	(1998)	
	c Add Amounts from column (e) for lines 15 _____ 16 _____ 17 _____ 20 _____ 21 _____				27c _____
	d Add Line 27a total _____ and line 27b total _____				27d _____
	e Public support (line 27c total minus line 27d total)				27e _____
	f Total support for section 509(a)(2) test Enter amount on line 23, column (e)				27f _____
	g Public support percentage (line 27e (numerator) divided by line 27f (denominator))				27g _____ %
	h Investment income percentage (line 18, column (e) (numerator) divided by line 27f (denominator))				27h _____ %
28 Unusual Grants	For an organization described in line 10, 11, or 12 that received any unusual grants during 1998 through 2001, prepare a list for your records to show, for each year, the name of the contributor, the date and amount of the grant, and a brief description of the nature of the grant Do not file this list with your return Do not include these grants in line 15				

**Part V Private School Questionnaire (See page 7 of the instructions.)**  
**(To be completed ONLY by schools that checked the box on line 6 in Part IV)**

	N/A	Yes	No
29 Does the organization have a racially nondiscriminatory policy toward students by statement in its charter, bylaws, other governing instrument, or in a resolution of its governing body?			
30 Does the organization include a statement of its racially nondiscriminatory policy toward students in all its brochures, catalogues, and other written communications with the public dealing with student admissions, programs, and scholarships?			
31 Has the organization publicized its racially nondiscriminatory policy through newspaper or broadcast media during the period of solicitation for students, or during the registration period if it has no solicitation program, in a way that makes the policy known to all parts of the general community it serves? If "Yes," please describe, if "No," please explain (if you need more space, attach a separate statement)			
32 Does the organization maintain the following			
a Records indicating the racial composition of the student body, faculty, and administrative staff?	32a		
b Records documenting that scholarships and other financial assistance are awarded on a racially nondiscriminatory basis?	32b		
c Copies of all catalogues, brochures, announcements, and other written communications to the public dealing with student admissions, programs, and scholarships?	32c		
d Copies of all material used by the organization or on its behalf to solicit contributions?  If you answered "No" to any of the above, please explain (if you need more space, attach a separate statement)	32d		
33 Does the organization discriminate by race in any way with respect to			
a Students' rights or privileges?	33a		
b Admissions policies?	33b		
c Employment of faculty or administrative staff?	33c		
d Scholarships or other financial assistance?	33d		
e Educational policies?	33e		
f Use of facilities?	33f		
g Athletic programs?	33g		
h Other extracurricular activities?  If you answered "Yes" to any of the above, please explain (if you need more space, attach a separate statement.)	33h		
34a Does the organization receive any financial aid or assistance from a governmental agency?	34a		
b Has the organization's right to such aid ever been revoked or suspended? If you answered "Yes" to either 34a or b, please explain using an attached statement	34b		
35 Does the organization certify that it has complied with the applicable requirements of sections 4 01 through 4 05 of Rev Proc 75-50, 1975-2 C B 587, covering racial nondiscrimination? If "No," attach an explanation	35		

**Part VI-A Lobbying Expenditures by Electing Public Charities** (See page 9 of the instructions.)

(To be completed ONLY by an eligible organization that filed Form 5768) N/A

Check  a if the organization belongs to an affiliated group Check  b If you checked "a" and "limited control" provisions apply

**Limits on Lobbying Expenditures**

(The term "expenditures" means amounts paid or incurred )

	(a) Affiliated group totals	(b) To be completed for ALL electing organizations
36 Total lobbying expenditures to influence public opinion (grassroots lobbying)	36	
37 Total lobbying expenditures to influence a legislative body (direct lobbying)	37	
38 Total lobbying expenditures (add lines 36 and 37)	38	
39 Other exempt purpose expenditures	39	
40 Total exempt purpose expenditures (add lines 38 and 39)	40	
41 Lobbying nontaxable amount Enter the amount from the following table-		
<b>If the amount on line 40 is-</b>		
Not over \$500,000		
Over \$500,000 but not over \$1,000,000		
Over \$1,000,000 but not over \$1,500,000		
Over \$1,500,000 but not over \$17,000,000		
Over \$17,000,000		
<b>The lobbying nontaxable amount is-</b>		
20% of the amount on line 40		
\$100,000 plus 15% of the excess over \$500,000		
\$175,000 plus 10% of the excess over \$1,000,000	41	
\$225,000 plus 5% of the excess over \$1,500,000		
\$1,000,000		
42 Grassroots nontaxable amount (enter 25% of line 41)	42	
43 Subtract line 42 from line 36 Enter -0- if line 42 is more than line 36	43	
44 Subtract line 41 from line 38 Enter -0- if line 41 is more than line 38	44	

Caution If there is an amount on either line 43 or line 44, you must file Form 4720

**4-Year Averaging Period Under Section 501(h)**

(Some organizations that made a section 501(h) election do not have to complete all of the five columns below

See the instructions for lines 45 through 50 on page 11 of the instructions )

Calendar year (or fiscal year beginning in)	Lobbying Expenditures During 4-Year Averaging Period				
	(a) 2002	(b) 2001	(c) 2000	(d) 1999	(e) Total
45 Lobbying nontaxable amount					
46 Lobbying ceiling amount (150% of line 45(e))					
47 Total lobbying expenditures					
48 Grassroots nontaxable amount					
49 Grassroots ceiling amount (150% of line 48(e))					
50 Grassroots lobbying expenditures					

**Part VI-B Lobbying Activity by Nonelecting Public Charities**

(For reporting only by organizations that did not complete Part VI-A) (See page 11 of the instr )

During the year, did the organization attempt to influence national, state or local legislation, including any attempt to influence public opinion on a legislative matter or referendum, through the use of

- a Volunteers
- b Paid staff or management (include compensation in expenses reported on lines c through h )
- c Media advertisements
- d Mailings to members, legislators, or the public
- e Publications, or published or broadcast statements
- f Grants to other organizations for lobbying purposes
- g Direct contact with legislators, their staffs, government officials, or a legislative body
- h Rallies, demonstrations, seminars, conventions, speeches, lectures, or any other means
- i Total lobbying expenditures (add lines c through h )

Yes	No	Amount
X		
	X	
	X	
	X	
	X	
	X	
	X	
	X	

If "Yes" to any of the above, also attach a statement giving a detailed description of the lobbying activities

SEE NOTE M



**Depreciation and Amortization**

OMB No 1545-0172

Form **4562**

(Including Information on Listed Property)

**2002**

Department of the Treasury  
Internal Revenue Service

▶ See separate instructions

▶ Attach to your tax return

Attachment  
Sequence No **67**

Name(s) shown on return **LIFE EXTENSION FOUNDATION, INC**

Identifying number  
**59-1746396**

Business or activity to which this form relates

**INDIRECT DEPRECIATION**

**Part I Election To Expense Certain Tangible Property Under Section 179**

Note: If you have any listed property, complete Part V before you complete Part I

1	Maximum amount See page 2 of the instructions for a higher limit for certain businesses	1	24,000
2	Total cost of section 179 property placed in service (see page 2 of the instructions)	2	
3	Threshold cost of section 179 property before reduction in limitation	3	200,000
4	Reduction in limitation Subtract line 3 from line 2 If zero or less, enter -0-	4	
5	Dollar limitation for tax year Subtract line 4 from line 1 If zero or less enter -0- If married filing separately see pg 2 of the Instr	5	
6	(a) Description of property	(b) Cost (business use only)	(c) Elected cost
7	Listed property Enter the amount from line 29	7	
8	Total elected cost of section 179 property Add amounts in column (c), lines 6 and 7	8	
9	Tentative deduction Enter the smaller of line 5 or line 8	9	
10	Carryover of disallowed deduction from line 13 of your 2001 Form 4562	10	
11	Business income limitation Enter the smaller of business income (not less than zero) or line 5 (see instructions)	11	
12	Section 179 expense deduction Add lines 9 and 10, but do not enter more than line 11	12	
13	Carryover of disallowed deduction to 2003 Add lines 9 and 10, less line 12	13	

Note Do not use Part II or Part III below for listed property Instead, use Part V

**Part II Special Depreciation Allowance and Other Depreciation (Do not include listed property)**

14	Special depreciation allowance for qualified prop (other than listed prop) placed in service during the tax year (see pg 3 of the Instr)	14	
15	Property subject to section 168(f)(1) election (see page 4 of the instructions)	15	
16	Other depreciation (including ACRS) (see page 4 of the instructions)	16	

**Part III MACRS Depreciation (Do not include listed property) (See page 4 of the instructions)**

**Section A**

17	MACRS deductions for assets placed in service in tax years beginning before 2002	17	10,698
18	If you are electing under section 168(i)(4) to group any assets placed in service during the tax year into one or more general asset accounts, check here		<input type="checkbox"/>

**Section B-Assets Placed in Service During 2002 Tax Year Using the General Depreciation System**

(a) Classification of property	(b) Month and year placed in service	(c) Basis for depreciation (business/investment use only-see instructions)	(d) Recovery period	(e) Convention	(f) Method	(g) Depreciation deduction
19a 3-year property						
b 5-year property						
c 7-year property						
d 10-year property						
e 15-year property						
f 20-year property						
g 25-year property			25 yrs		S/L	
h Residential rental property			27.5 yrs	MM	S/L	
i Nonresidential real property			39 yrs	MM	S/L	

**Section C-Assets Placed in Service During 2002 Tax Year Using the Alternative Depreciation System**

20a Class life					S/L	
b 12-year			12 yrs		S/L	
c 40-year			40 yrs	MM	S/L	

**Part IV Summary (see page 6 of the instructions)**

21	Listed property Enter amount from line 28	21	
22	Total Add amounts from line 12, lines 14 through 17, lines 19 and 20 in column (g), and line 21 Enter here and on the appropriate lines of your return Partnerships and S corporations-see instr	22	10,698
23	For assets shown above and placed in service during the current year, enter the portion of the basis attributable to section 263A costs	23	

For Paperwork Reduction Act Notice, see separate instructions

Form **4562** (2002)

**Part V Listed Property** (Include automobiles, certain other vehicles, cellular telephones, certain computers, and property used for entertainment, recreation, or amusement.)

Note For any vehicle for which you are using the standard mileage rate or deducting lease expense, complete only 24a, 24b, columns (a) through (c) of Section A, all of Section B, and Section C if applicable.

**Section A-Depreciation and Other Information** (Caution See page 8 of the instructions for limits for passenger automobiles)

24a Do you have evidence to support the business/investment use claimed?		Yes	No	24b If "Yes," is the evidence written?		Yes	No	
(a) Type of prop (list vehicles first)	(b) Date placed in service	(c) Business/ investment use percentage	(d) Cost or other basis	(e) Basis for depreciation (business/investment use only)	(f) Recovery period	(g) Method/ Convention	(h) Depreciation deduction	(i) Elected section 179 cost
25 Special depreciation allowance for qualified listed property placed in service during the tax year and used more than 50% in a qualified business use (see page 7 of the instructions)								
							25	
26 Property used more than 50% in a qualified business use (see page 7 of the instructions)								
		%						
		%						
27 Property used 50% or less in a qualified business use (see page 7 of the instructions)								
		%				S/L-		
		%				S/L-		
28 Add amounts in column (h), lines 25 through 27 Enter here and on line 21, page 1							28	
29 Add amounts in column (i), line 26 Enter here and on line 7, page 1								29

**Section B-Information on Use of Vehicles**

Complete this section for vehicles used by a sole proprietor, partner, or other "more than 5% owner," or related person

If you provided vehicles to your employees first answer the questions in Section C to see if you meet an exception to completing this section for those vehicles

	(a)		(b)		(c)		(d)		(e)		(f)	
	Vehicle 1	Vehicle 2	Vehicle 3	Vehicle 4	Vehicle 5	Vehicle 6	Vehicle 1	Vehicle 2	Vehicle 3	Vehicle 4	Vehicle 5	Vehicle 6
30 Total business/investment miles driven during the year (do not include commuting miles- see page 2 of the instructions)												
31 Total commuting miles driven during the year												
32 Total other personal (noncommuting) miles driven												
33 Total miles driven during the year Add lines 30 through 32												
34 Was the vehicle available for personal use during off-duty hours?	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No
35 Was the vehicle used primarily by a more than 5% owner or related person?												
36 Is another vehicle available for personal use?												

**Section C-Questions for Employers Who Provide Vehicles for Use by Their Employees**

Answer these questions to determine if you meet an exception to completing Section B for vehicles used by employees who are not more than 5% owners or related persons (see page 8 of the instructions)

	Yes	No
37 Do you maintain a written policy statement that prohibits all personal use of vehicles, including commuting by your employees?		
38 Do you maintain a written policy statement that prohibits personal use of vehicles, except commuting, by your employees? See page 8 of the instructions for vehicles used by corporate officers, directors, or 1% or more owners		
39 Do you treat all use of vehicles by employees as personal use?		
40 Do you provide more than five vehicles to your employees, obtain information from your employees about the use of the vehicles, and retain the information received?		
41 Do you meet the requirements concerning qualified automobile demonstration use? (See page 9 of the instructions) Note If your answer to 37, 38, 39, 40, or 41 is "Yes," do not complete Section B for the covered vehicles		

**Part VI Amortization**

(a) Description of costs	(b) Date amortization begins	(c) Amortizable amount	(d) Code section	(e) Amortization period or percentage	(f) Amortization for this year
42 Amortization of costs that begins during your 2002 tax year (see page 9 of the instructions)					
43 Amortization of costs that began before your 2002 tax year				43	26,667
44 Total Add amounts in column (f) See page 9 of the instructions for where to report				44	26,667

Form 990, Part I, Line 6b - Rental Expenses

<u>Description</u>	<u>Deduction</u>
RENT EXPENSE - REDWOOD	71,490
DEPRECIATION EXP	<u>10,698</u>
TOTAL	<u><u>82,188</u></u>

Statement 1 - Form 990, Part II, Line 43 - Other Functional Expenses

<u>Description</u>	<u>Total Expenses</u>	<u>Program Service</u>	<u>Mgt &amp; General</u>	<u>Fund- Raising</u>
	\$	\$	\$	\$
EXPENSES				
RENT	4,751		4,751	
BANK CHARGES	3,052		3,052	
CHAR CONTRIBUTIONS - ALCOR	100,117		100,117	
MAINTENANCE & REPAIRS	2,300		2,300	
OFFICE EXPENSES	14,643		14,643	
TAXES	173		173	
TOTAL	<u>\$ 125,036</u>	<u>\$ 0</u>	<u>\$ 125,036</u>	<u>\$ 0</u>



**Form 990, Part IV, Line 58 - Other Assets**

<u>Description</u>	<u>Beginning of Year</u>	<u>End of Year</u>
GOODWILL	\$ 400,000	\$ 400,000
ACCUM AMORTIZATION-GOODWILL	-133,335	-160,002
TOTAL	<u>\$ 266,665</u>	<u>\$ 239,998</u>

**Form 990, Part IV, Line 65 - Other Liabilities**

<u>Description</u>	<u>Beginning of Year</u>	<u>End of Year</u>
DEPOSIT PAYABLE	\$ 3,136	\$ 5,786
TOTAL	<u>\$ 3,136</u>	<u>\$ 5,786</u>

LIFE EXTENSION FOUNDATION, INC.  
2002 – FORM 990

NOTE A – PART 1 – LINE 8 a,b,c, - SALE OF SECURITIES GAIN OR (LOSS)

	<u>Sales Date</u>	<u>Selling Price Line 8a</u>	<u>Cost Line 8b</u>	<u>Gain (Loss) Line 8c</u>
140 shares- KONINKLIJKE PHILIPS ELECTRONICS NV	01/09/02	\$ 4,241	\$ 4,171	\$ 70
40 shares- TELEFONICA SA NEW EUR1	01/25/02	8	-	8
1600 shares-BANCO SANTANDER CENTRAL	02/11/02	12,200	3,405	8,795
190-AVENTIS SA	02/21/02	13,617	13,491	126
300 shares-VIVENDI UNIVERSAL	02/21/02	10,919	16,427	(5,508)
75 shares-SAP AG ORD NPV	02/21/02	9,955	9,770	185
110 shares-TOTAL FINA ELF EUR1D	02/21/02	15,462	15,710	(248)
130 shares-E ON AG NPV	02/21/02	6,335	6,734	(399)
70 shares-ALLIANZ AG NPV	02/21/02	14,732	16,579	(1,847)
494 shares-KONINKLIJKE AHOLD NV EURO 25	02/21/02	12,045	14,374	(2,329)
1040 shares-TEEFONICA SA EUR1	02/21/02	11,396	13,918	(2,522)
160 shares-DSM NV EUR3	02/21/02	5,869	5,842	27
580 shares-NOKIA OYJ EURO 06	02/21/02	11,682	14,955	(3,273)
140 shares-ST MICROELECTRONICS	02/21/02	4,052	4,742	(690)
436 shares-KONINKLIJKE PHILIPS ELECTRONICS NV	02/21/02	11,155	12,948	(1,793)
160 shares-NOVO-NORDISK AS DKK2	02/21/02	6,104	6,543	(439)
180 shares-PEUGEOT SA EUR1	02/21/02	7,522	7,653	(131)
200 shares-ROCHE HLDG AG GENUSSCHEINE	02/21/02	13,396	14,275	(879)
200 shares ADECCO SA CHF1	02/21/02	11,168	14,872	(3,704)
300 shares-SUEZ EUR2	02/21/02	8,501	9,082	(581)
70 shares-NESTLE SA CHF1	02/21/02	15,377	14,925	452
265 shares-UBS AG CHF2 80	02/21/02	12,138	13,375	(1,237)
2450 shares-ENEL EUR1	02/21/02	13,381	13,808	(427)
800 shares-ENI EUR1	02/21/02	10,581	10,029	552
500 shares-ING GROEP N V CVA	02/21/02	11,434	16,645	(5,211)
470 shares-FORTIS NPV	02/21/02	10,068	12,178	(2,110)
350 shares-BNP PARIBAS EUR2	02/21/02	15,830	15,659	171
20 shares-TELEFONICA SA EUR1	04/11/02	4	5	(1)
20 shares-TELEFONICA SA EUR1	04/26/02	220	224	(4)
12,800 shares-ISHARES LFTSE WORLD COM INC SR NOTES DTD 8/11/98, DUE 8/15/05	08/15/02	84,756	91,117	(6,361)
	12/10/02	<u>42,270</u>	<u>50,161</u>	<u>(7,891)</u>
		<u>\$406,418</u>	<u>\$443,617</u>	<u>\$(37,199)</u>

LIFE EXTENSION FOUNDATION, INC.  
2002 - FORM 990

NOTE B - PART 1 - LINE 20

Increase in net realizable value of securities for year ended December 31, 2002.

NOTE C - PART II - LINE 22 - GRANTS AND ALLOCATIONS

Stasis Foundation	\$	634
Advanced Biosciences		11,500
Echelon Sciences		4,492
21 <sup>st</sup> Century Medicine, Inc		1,590,000
Critical Care Research, Inc.		770,000
Life Extension Genetics, Inc		700
Kryos Biomedical, Inc.		2,500
University of Arkansas		88,400
University of California - Regents		51,050
Lifespan Genetics, Inc.		609,755
Suspended Animation		<u>752,600</u>
	<u>\$</u>	<u>3,881,631</u>

Tax status and addresses will be provided upon request

NOTE D - PART III STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS

The mission of The Life Extension Foundation is to educate the public about and to support and fund scientific research to develop new methods of preventing and reversing age-related diseases, the aging process itself, and the processes by which we die

During the year 2002, The Life Extension Foundation continued to fund numerous research and educational projects They included the following

1) Research to identify and investigate the functions of genes involved in aging and experimental models of extended life span and disease prevention at laboratories in Southern California, Baltimore, Maryland and Dallas, Texas The objective of this research is to develop pharmaceuticals, nutraceuticals and other methods of improving health and extending life span in humans

2) Research at the University of Arkansas to study the effects on longevity and other measures of health of nutritional compounds that boost DNA methylation The purpose of this research is to determine whether these agents can improve healthy life span in humans

LIFE EXTENSION FOUNDATION, INC  
2002 - FORM 990

NOTE D - PART III STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS  
(CONTINUED)

3) Research at a private laboratory in Southern California to cryopreserve complex biological systems via a process called vitrification. This process permits tissues and organs to be taken down to very low temperatures without the formation of damaging ice crystals. The objectives of this research are to develop effective methods of long-term storage of tissues and organs for transplantation in humans, and to develop perfected human suspended animation.

4) Research at a private laboratory in Southern California to develop an automated, portable system to place humans in profound hypothermia (cooled). The purposes of this research are to enable medical personnel in the field and in hospitals to prevent damage in patients who suffer heart attacks, strokes, closed head injuries and other conditions. This new technology will also contribute to therapies to prevent brain damage, resuscitate patients, and perfect human suspended animation.

5) Research to create and construct a large (6-acre) facility for several purposes: to conduct research into methods to prevent and reverse aging, to develop methods to regenerate tissues and organs, to store cells, tissues and organs for transplant, to store embryos of species near extinction; to develop human suspended animation, to care for patients preserved at ultra-low temperatures for possible future revival, and to develop nanotechnologic and other methods to repair and rebuild cells in human patients.

6) Support of an educational program by the Prostate Cancer Research Institute (PCRI). Anyone who wishes to be on PCRI's mailing list receives copies of the organization's newsletter. The Prostate Cancer Research Institute ([www.prostate-cancer.org](http://www.prostate-cancer.org)) is a 501 (3) organization, located in Marina del Rey, California and is headed by the renowned medical oncologist Stephen Strum, MD.

The Life Extension Foundation (LEF) funds radical scientific and educational programs for aging control and extended health and longevity. The following is a detailed report of the progress achieved during the 2002 year by several of the research facilities funded by LEF.

LIQUID VENTILATION DEVELOPMENT

Critical Care Research, Inc., a research facility owned more than 80% by LEF has advanced significantly in the search for a technique of cooling by chilled fluorocarbon lung lavage, which would bring about rapid brain cooling for purposes of resuscitation or cryonics, without doing significant lung damage. Work on this chief project has advanced on three fronts.

LIFE EXTENSION FOUNDATION, INC.  
2002 – FORM 990

NOTE D - PART III STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS  
(CONTINUED)

1. **Production of a lavage device.** Heat exchanger development has been undertaken at CCR. The pump part of this project was originally contracted out to Korr Medical in Salt Lake City, in 2001. As reported previously, Korr was able to produce a computerized semi-portable device weighing about 35 lbs that ran on external compressed gas (50 psi), an external vacuum pump (10 lbs), and A C power. An additional 12 lb heat exchanger (developed at CCR) and 20 lbs of fluorocarbon fluid and reservoir were needed, for a device total weight between 75 and 80 lbs (portable in several modules). This was by comparison to the 1<sup>st</sup> generation device which weighed over 300 lbs. CCR is still testing new and lighter designs prior to formally packaging the portable machine.

2. **Development of the Liquid Ventilation Protocol; Lavage Volume and Technique.** We have used the working Korr devices and heat exchangers meanwhile to test certain critical parameters for lung lavage in living animals. These parameters are device-independent, and depend on type of fluorocarbon and its flow characteristics, the interaction of the animal's lungs with the fluorocarbon, and the amounts, temperature, and timing with which the liquid is delivered.

At the time of our last report, our lung lavage protocol was accomplished with loads of fluorocarbon ranging from 40 mL/kg to 10 mL/kg. We had noted decreasing efficiency going from 20 mL/kg to 10 mL/kg lavage sizes. We had hypothesized that lavages of 10 mL/kg were near the lower limit of volume which could be efficiently transferred because of the known dead space of about 7 mL/kg in the dog. However, upon further experimentation, some of which was carried out because of patent-related matters, we found that smaller lavage volumes DID turn out to be unexpectedly effective. We believe that this happens in the same way that panting and high frequency low-volume ventilation is effective for gas transfer, so long as certain mixing conditions are ensured. One of these conditions turned out to be steady lung inflation while infusion is in progress.

In the process, we have discovered that mechanical ventilator support is a very poor way to provide oxygen during lung lavage, since a ventilator cannot coordinate with the liquid inflow and outflow cycles, in a way that exposes the lungs to minimum pressure. However, a protocol to do this is easily done by a human operator with a manual bag-valve device (a bag full of oxygen which connects to the endotracheal tube, and which provides ventilation when squeezed by hand). Since such a device will be used anyway along with lung lavage to provide oxygen, whenever lung lavage is used in the future in emergency medical or cryonics situations. We have switched to this technique as a way of minimizing lung pressure damage. We have also discovered what we believe is the proper technique for gas ventilation during lung lavage (gas ventilation is necessary to best provide oxygen and remove carbon dioxide).

Using bag-valve techniques and low viscosity fluorocarbons, we have been able to cool at rates of 18 C (32 F) per hour, using individual lavages of only 3 to 4 mL/kg, delivered and removed quite rapidly (13 second lavage cycle). These produce no visible lung damage at all, and only very minor physiologic signs (slight decrease in oxygen levels) in animals on the next day after lavage.

LIFE EXTENSION FOUNDATION, INC.  
2002 - FORM 990

NOTE D - PART III STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS  
(CONTINUED)

One of the outcomes of our large-animal survival research is the discovery that a previously unknown form of damage may take place in liquid ventilated lungs, but that the extent of the damage is not evident until some time has passed after liquid has been introduced to the lung. This damage produces obstruction and wheezing, and very low oxygen levels on the day after lavage. Researchers who evaluate and autopsy their animals shortly after the end of liquid lavage experiments (by far the most common practice in other institutions) never see this damage, and it is not apparent in the animal's lung performance. However, it will be extremely important to evaluate and minimize this syndrome prior to any medical development of lung lavage.

A second major variable in the amount of damage seen in lungs on the day following lung lavage, is what type of perfluorocarbon chemical is used. Almost all human clinical study of PFC liquid breathing, and much of the study in animals, has been done with a pharmaceutical chemical called perfluorooctylbromide (Trade name Perflubron). But Perflubron has a high freezing point which makes it unsuitable for cooling uses, and in addition it has failed to win FDA approval even for non-cooling ventilation uses. It may have intrinsic problems, but we have been unable to obtain enough of it to test it directly ourselves, for the pharmaceutical company which holds the patents on it will not make it available for any study which is not pre-approved.

Although Perflubron is not suitable and also unavailable, there are many other perfluorochemical liquids with viscosity and freezing point properties which make them suitable for use in cold lung lavage. In full dog cooling experiments we have recently tested nine different commercial preparations of seven basic perfluorochemical liquids with viscosity and freezing point properties which make them suitable for use in cold lung lavage. In full dog cooling experiments we have recently tested nine different commercial preparations of seven basic perfluorochemicals, plus some combinations of chemicals, in search of a suitable working fluid. We have found that a fluorocarbon's long term effects in the lung can be partly predicted by its viscosity (which affects needed ventilation pressure) and by its vapor pressure (which affects its tendency to escape into the lung tissue to cause damage). Fluids with an intermediate value of both of these qualities are best, but we have found surprises. Presently we are working on a benign fluid which we hope to patent. This could not have been found except in a large animal model (which permits control of ventilation pressures by hand) and a survival model, since many toxic properties of fluids are not evident for at least 24 hours, as noted. These factors allowed Critical Care Research to make the discovery.

**3. Heat Exchanger Development.** As noted in our previous report, we have been able to adapt commercial disposable renal dialysis equipment into an excellent heat exchanger design. We have used this basic cooling method in our last 45 procedures on dogs. We have submitted a patent for the use of capillary dialyzers to cool fluorocarbon, and to cool blood directly.

LIFE EXTENSION FOUNDATION, INC.  
2002 - FORM 990

NOTE D - PART III STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS  
(CONTINUED)

COLLABORATIVE VENTURES (10% OF TOTAL TIME)

1. **Studies of Vitamin E Emulsion** In dog resuscitation studies performed at Critical Care Research, Inc in 1997, it was discovered that a mixture of antioxidants delivered in a vitamin E emulsion directly into the bloodstream, could produce survival of animals from as long as 15 minutes of cardiac arrest. The emulsion was difficult to make, however.

Recently we have discovered a way to easily make and stabilize this emulsion. It can be given intravenously and serves as a delivery platform for a number of lipid soluble drugs. We have contacted a number of institutions who are interested in using the proprietary vehicle as delivery emulsion for the following purposes:

A. *A delivery vehicle for propofol* Presently only two companies prepare this IV anesthetic, because of its difficulty. The parent anesthetic drug propofol is a very inexpensive off-patent bulk chemical which does not dissolve in water. Through propofol only costs less than 50 cents a gram to commercially produce, presently IV preparation of this drug is sold at \$100 per gram of drug, because only two companies can make IV compatible emulsions to hold it. The present propofol market is \$400 million per year. We have created our own version of propofol using our own inexpensive emulsion system, and tested it on dogs, where it works well. We are looking for a market for an inexpensive version of this, and are told that the large animal veterinary market is the place to begin, because expense prohibits using standard commercial propofol in horse anesthesia. We are presently in contact with a large animal anesthesia specialist (E. P. Steffey) at UC Davis Veterinary School, who is eager to test our propofol on horses. It is presently awaiting approval by institutional animal testing committee, before this begins.

Our propofol emulsion has an advantage over commercial propofol preparations in being sterilizable directly by cold-filtration, a process that is not possible with the large emulsions used in present commercial propofol solutions.

Our institutional veterinarian, Dr. Wayne Davis, has used our propofol emulsion to induce anesthesia in a surgical dog, and believes that it possibly has superior performance characteristics to the commercial preparation, since it allowed anesthesia induction without a period of apnea (breathing pause). He will continue to test the emulsion at his clinic.

LIFE EXTENSION FOUNDATION, INC.  
2002 - FORM 990

NOTE D - PART III STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS  
(CONTINUED)

**B** *A delivery vehicle for xenon* Presently the rare, inert and expensive gas *xenon* is used as a contrast agent for the brain in contrast enhanced CT. The technique can directly measure brain blood flow, far more rapidly than MRS techniques, and is therefore useful in immediate stroke evaluation. However, the gas is presently delivered to the patient by a rebreather mask system, which is uncomfortable and causes waste of xenon. There may be a much better way

Xenon is 20 times more soluble in lipids than water, and we believe our lipid-like emulsion can be used to hold Xenon for use in rapid xenon-CT. The xenon would then be given directly into the patient's bloodstream, wasting nothing, and not requiring a mask. We are in contact with the chief xenon-CT specialist in the U.S., Dr. Howard Yonas, and he has agreed to test our emulsion in his animal model. He has arranged for a tank of xenon gas to be shipped to us. We now have it, and will be preparing test xenon emulsions shortly. Again, we are waiting for animal use committee approval (Dr. Yonas works with monkeys)

**C** *A delivery vehicle for novel brain-protective free radical trap drugs* Personnel from CCR attended this year's STROKE society conference in Phoenix, Arizona. One of the presentations involved the action of the novel and patented chemical compound STAZN, an experimental free radical trap drug invented by Dr. David A. Becker at Florida International University. This drug almost completely prevents the severe half-brain stroke injury in a particular rodent brain ischemia model. The drug is a nitrene spin-trap (by spin-adduct formation), similar in mechanism of action to PBN, but much more potent. However, it is not soluble in water and must be given to animals dissolved in 100% DMSO (could never be injected into human patients). Dr. Becker agreed, and we have sent him some proprietary emulsion base. He reports that our emulsion dissolves STAZN well. We await the results of his animal studies with it.

These are samples only. There is a very large market for injectable lipid soluble drugs which is only partly trapped.

**D** *A delivery vehicle for vitamin E in skin care products* We have recently found to our surprise that vitamin E in almost all skin care products is put there as the inactive ester, instead of the free alcohol which actually has radical trapping and antioxidant properties. The ester is used and useful in oral vitamin preparations, but it must be processed in the gut to active vitamin. There is no evidence that it is processed by skin, or has vitamin or antioxidant activity on skin. Our vitamin E emulsion uses the free vitamin E alcohol in a stable base, and the emulsion also forms micelles which (like liposomes) have been found to penetrate at least the outer skin layer. We are working with a developer of skin care products to see if our vitamin E emulsion can be used as the base for a skin care product which actually uses the antioxidant power of vitamin E it contains. The emulsion also makes a natural delivery vehicle for melatonin and CoQ10 which have also been used widely in the skin care industry, but which are not freely water-soluble.



LIFE EXTENSION FOUNDATION, INC.  
2002 - FORM 990

NOTE D - PART III STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS  
(CONTINUED)

E *Delivery vehicle for animal vitamin products* We have been in contact with Rob Stuart at Stuart Products, which develops products for the agricultural industry. We are told that the pig and poultry industry relies heavily on injectable vitamin E because mortality of young animals is very high without it. Oral vitamin E is not absorbed because it cannot be emulsified properly by the digestive system of piglets and poults (juvenile birds). Dr. Stuart is very interested in our emulsion as an oral vitamin delivery system.

Another facility owned more than 80% by LEF is 21<sup>st</sup> Century Medicine, whose mission is to perfect methods of cryogenic storage of complex living systems, including organs such as kidneys and even brains. One major goal is to be able to replace age-ravaged, failing organs with fresh organs retrieved when and where desired from a permanent organ bank. Organ failure is the leading cause of age-related death, so if the Company's technology can make organ replacements more feasible in the future, the overall human mortality curve could be shifted to the right, that is, to higher average lifespans. Another goal is to prevent not only the failure of the body but also of the mind by using brain tissue transplants to cure diseases such as Parkinson's disease, in which cell death in a specific part of the brain can be corrected by the transplantation of replacement cells. Again, such transplants will only be practical if banks of living brain tissue can be established. Further, new anti-aging drugs intended to prevent or treat brain aging will have to be screened for their effects on both brain cells and liver cells, which metabolize drugs and often convert them into toxic byproducts, before human trials can be considered. Drug companies' drug screening efforts currently rely on liver cells that are basically dead due to the difficulty of freezing liver tissue. 21<sup>st</sup> Century Medicine, however, has shown that it can bank both liver and brain tissue in good condition for drug discovery and drug screening purposes that can benefit the quest to beat the effects of aging.

Right now, even if organ banks could eliminate most of the problems of matching organs to recipients to reduce rejection, transporting the organs to where they need to go, scheduling surgery at a time and a place that is best for both the patient and the transplant surgeon, and even preconditioning the recipient to avoid rejection altogether, there aren't enough organs to meet the demand. This need is being met by dozens of tissue engineering companies, which are using their multi-billion dollar investment capital to learn how to build replacement tissues and organs in the laboratory. In addition, companies like Advanced Cell Technology and Geron are striving to create organs grown from stem cells derived from the patient who needs the organs. All of these efforts, however, will require banking of the laboratory-produced tissue replacements because there needs to be some flexibility between the time an organ is produced and the time it is used, and because maintenance of the organ at high temperatures for months or years before use would be dangerous and prohibitively expensive.

LIFE EXTENSION FOUNDATION, INC.  
2002 – FORM 990

NOTE D - PART III STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS  
(CONTINUED)

21<sup>st</sup> Century Medicine currently has 4 major projects underway. The first is to prove out its cryopreservation technology on a simple system that can provide immediate benefits to hundreds of thousands of people world-wide. The system is the cornea, which causes blindness as it deteriorates and becomes cloudy with age. The Company has shown that it can cool corneas to as low as  $-170^{\circ}\text{C}$  ( $-274^{\circ}\text{F}$ ), which is cold enough to prevent changes from taking place even over hundreds of years, and rewarm the cornea without loss of any function that the Company or a cooperating eye bank have been able to measure to date. The next step is transplants in animal models and then in humans. World-wide, well over 250,000 patients with opaque or damaged corneas could benefit from this breakthrough in low temperature preservation technology. Although the method of preservation is quick and simple, the Company would like eventually to automate the whole procedure to eliminate human error and make the entire process almost effortless.

The second major project at 21<sup>st</sup> Century Medicine is also intended to provide major benefits to patients in the near term, while serving as a bridge to a positive working relationship between the Company and the organ transplant community upon which it ultimately depends. Right now, about 20,000 organs are transplanted each year in the United States, and an approximately equal number are transplanted in the rest of the world. All of these organs have to be flushed with a preservation solution in order to remove blood and stabilize the organs for the 4-36 hours currently available for organ allocation, transportation, and transplantation. As a side benefit of our research on the cryogenic banking of organs, we have been able to develop a new organ flushing solution that seems to have a number of advantages over the current world leader, known as UW (or University of Wisconsin) solution (trade name Viaspan™). First, the new solution is more pleasant to use because it displaces blood much more rapidly and easily than UW solution and it isn't sticky like UW solution. Second, the new solution is made from less expensive ingredients than UW solution, which means better consumer protection against spiraling costs. Third, the new solution contains only ingredients that are safe for delivery into the human body and therefore, unlike UW solution, there is no need to flush the solution out of the organ before the organ is transplanted. Finally, of course, there is the all-important observation that the new solution seems to be better than UW solution for the actual job of preserving kidneys for periods of 2-4 days in experiments conducted so far involving both rabbit and dog kidney transplants. This project is currently supported by a grant from the National Institute of Health (NIH). We are also developing a different solution and method that is specifically tailored to the preservation of the heart and that has extended the preservation time possible for dog hearts from the current clinical limit of 4 hours to a remarkable 45 hours and beyond. This technique is being supported by a separate NIH grant.

LIFE EXTENSION FOUNDATION, INC.  
2002 – FORM 990

NOTE D - PART III STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS  
(CONTINUED)

Our second project has already been of benefit to our third project, which is the current centerpiece of our efforts. This third project is to be able to demonstrate, for the first time, that a mature and sensitive mammalian organ can be cooled to cryogenic temperatures, rewarmed, and transplanted with the subsequent life support ability. Our present model is the rabbit kidney because both the housing and the transplantation procedures for this species are feasible and inexpensive and because more is known about the cryobiology of the rabbit kidney than of any other organ. The road to the cryogenic banking of the rabbit kidney has been a long and difficult one, dating back to the 1970's the present approach, which allows us to avoid freezing and thawing altogether even though we cool to more than 200°F below zero, was first conceived of in 1980 at the American Red Cross and is called "vitrification" or glass formation, a glass being a kind of "hard liquid" that is basically too cold to flow. Since then, the main goal has been to find solutions and methods of use of these solutions that allow vitrification of whole organs without being biologically damaging. Progress between 1980 and 1997 was considerable, but it was really a series of breakthroughs starting in 1998 and made at 21<sup>st</sup> Century Medicine that have brought the goal of successful organ banking within reach. These breakthroughs are both basic and applied, the applied successes serving to validate the utility of the basic observations and demonstrate their general applicability, which is necessary to cover all of the cell types in a complex organ or series of organs. A partial list of supporting breakthroughs other than those already mentioned is as follows:

- Development of a new family of vitrification solutions with unprecedentedly low toxicity in combination with an unprecedented stability against ice formation
- Development of the only two synthetic "ice blockers" (antinucleators) known to be available and practical for general purpose use
- Development of a patent pending means of avoiding "chilling injury" during cooling to cryogenic temperatures
- Development of special physiological support solutions that maintain cell viability and maximize the ability of vitrification solutions to resist ice formation
- Development of a successful method for the vitrification of ova with little injury
- Development of successful methods for the vitrification of organ slices (rat renal medulla, rabbit and rat renal cortex, rat liver, and rat hippocampus) with little injury
- Development of proprietary methoxylated cryoprotectants that permeate cells faster and achieve higher glass transition temperatures than convention agents
- Development of optimal protocols for the addition and washout of vitrification solutions
- Development of a unique theory of cryoprotectant toxicity that quantitatively accounts for the toxicities of 20 different vitrification solutions
- Development of a new temperature-control technology that makes storage and shipping of a small or large vitrified specimens safe and convenient

LIFE EXTENSION FOUNDATION, INC.  
2002 – FORM 990

NOTE D - PART III STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS  
(CONTINUED)

Using these novel tools, the Company first tested a new solution of water-replacing, glass-forming chemical at a concentration that was formerly 100% fatal with a previous best formula. By pumping the solution through the vascular system of the kidneys in a complex procedure of gradual addition and removal of the chemical agents, we found that all rabbit kidneys so treated appeared to be fully undamaged, because their performance after transplantation was even better than previous transplants of untreated control kidneys. Next, the Company showed that such kidneys could be cooled to  $-22^{\circ}\text{C}$  ( $-8^{\circ}\text{F}$ ) with little damage. But to really vitrify these kidneys, a higher concentration of chemical agents was needed, and this higher concentration had to be delivered at this lower temperature. After some methodological development, it became possible to load this enormously concentrated (9.3M) solution (known as M22) at  $-8^{\circ}\text{F}$ , wash it out, and recover all kidneys with normal post-transplant function after a few days of renal recovery. This contrasts greatly with results obtainable before 1998, in which many kidneys were killed by a similar treatment and the surviving kidneys were badly and permanently damaged. M22 is theoretically sufficiently stable to allow successful vitrification and rewarming of the rabbit kidney, and we are pursuing this goal.

Our fourth major project builds upon the successes of the third and involves the cryopreservation by vitrification of the mammalian brain. In addition to providing drug discovery teams, neuroanatomists, neurobiologists, doctors, and brain banks with valuable material for medical and scientific use, the ability to bank the mammalian brain in a viable condition has the potential to eliminate the practice of cryonics, in which human beings are preserved using damaging methods in the hope of eventual future revival and repair, and replace it with true suspended animation, in which human patients can be preserved using methods known to be reversible at the time they are applied.

This could amount to a cure for any presently-fatal disease that did not involve destruction of the brain itself, including the disease of aging, and has clear commercial and humanitarian potential. The brain cryopreservation project is designed to unfold in several stages. The first phase involves the design of techniques that allow the rabbit brain to be vitrified and rewarmed without structural injury from ice formation as detected by electron microscopy. This phase has already been accomplished successfully using M22, although confirmatory studies are still underway. The successful use of M22 in this phase is encouraging, because we were able to show that brain slices vitrified using an analogous solution were as viable and structurally robust as control brain slices after rewarming. That observation will be amplified beginning this year thanks to the hiring of a professional neurobiologist who will study the electrical properties of vitrified and rewarmed brain slices and determine exactly how well preserved these slices are. Phase two will attempt to show that vitrified and rewarmed rabbit brains still look good in the electron microscope when the cryoprotective agent has been removed. Once Phase two has been successfully completed, tests on the actual functionality of the vitrified and rewarmed whole rabbit brain will be considered.

LIFE EXTENSION FOUNDATION, INC.  
2002 - FORM 990

NOTE D - PART III STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS  
(CONTINUED)

21<sup>st</sup> Century Medicine believes its technologies will have lasting value. Even after aging and disease are abolished and organ transplants are no longer necessary for these reasons, there will always be accidents in which lives can be saved by organ replacement, and for that purpose, a replacement organ will have to be available right away, without forewarning, from a local organ bank, and 21<sup>st</sup> Century Medicine technologies will continue to make that life-saving maneuver possible. Furthermore, extension of brain and organ vitrification techniques to whole people could be an essential development for the exploration of the universe.

NOTE E - PART IV LINE 51a - NOTES RECEIVABLE

Note Receivable - Life Extension Foundation Buyers Club, Inc	\$ 1,511,398	(Sale of Business)
Note Receivable - Life Extension Foundation Buyers Club, Inc.	13,500,111	(Current & Accrued Royalties)
Note Receivable - 21 <sup>st</sup> Century Medicine, Inc.	48,562	
Mortgage Receivable - 21 <sup>st</sup> Century Medicine, Inc	<u>266,920</u>	
	<u>\$ 15,326,991</u>	

NOTE F - PART IV LINE 54 - INVESTMENTS IN SECURITIES

Bonds - Federal Agencies & US Government	\$ 1,406,542
Bonds - Municipal	553,288
Bonds - Corporate	2,096,200
Bonds & Funds - International	1,616,400
Closed-End Fund	<u>46,862</u>
Total Investments	<u>\$ 5,719,292</u>

NOTE G - PART IV LINE 56 - INVESTMENTS - OTHER

Cash Surrender Value - Life Insurance Annuity-Beneficiary is Life Extension Foundation, Inc	<u>\$ 323,764</u>
---	-------------------

NOTE H - PART VI - ITEM 83B

The membership fee is \$75.00 per year. Under Section 6115, no written notice is required regarding Quid Pro Quo contributions when the membership fee is \$75.00 or less.

LIFE EXTENSION FOUNDATION, INC.  
2002 - FORM 990

NOTE I - SCHEDULE A - PART III LINE 1 AND PART VI-B

Life Extension Foundation Buyers club, Inc ("Buyers Club"), a for-profit corporation funds and publishes the Life Extension Magazine and distributes the magazine to all Life Extension Foundation members. This magazine serves as a means of describing the vitamin supplement products that buyers club sells to the public, in addition to the informative articles that are carefully researched and presented in the Magazine that are of interest to the Foundation's members. Occasionally, the Magazine publishes articles highlighting legislation that affects the interests of the Foundation members. However, the Magazine is fully funded by Buyers Club. There are no lobbying expenditures funded by the Foundation.

NOTE J - PART VI LINE 82A

Life Extension Foundation Buyers Club, Inc. donated certain products and promotional material to Life Extension Foundation, Inc. for distribution by the Foundation to Foundation's new and renewing members.

NOTE K - PART VI LINE 88 AND PART IX

<u>Ownership</u>	<u>Business Activity</u>	<u>Income</u>	<u>EOY Assets</u>
80-95%	21 <sup>ST</sup> Century Medicine, Inc. 10743 Civic Center Drive Rancho Cucamonga, CA 91730 (33-0559567)	<u>\$(1,523,550)</u>	<u>\$ 1,707,276</u>
80 6%	Critical Care Research, Inc. 10743 Civil Center Drive Rancho Cucamonga, CA 91730 (95-4750143)	<u>\$ (681,616)</u>	<u>\$ 1,577,320</u>
100%	California Advanced Biosciences, Inc 8460 Red Oak Street Rancho Cucamonga, CA 91730 (33-0849929)	<u>\$ (27,370)</u>	<u>\$ 806</u>
99 17%	Life Research, Inc. FKA Life Span Genetics, Inc 3972 Claitor Way San Jose, CA 95132 (33-0898013)	<u>\$(527,539)</u>	<u>\$(115,943)</u>

LIFE EXTENSION FOUNDATION, INC  
2002 – FORM 990

NOTE K – PART VI LINE 88 AND PART IX (CONTINUED)

88.89%	Life Extension Genetics, Inc. 3972 Clator Way San Jose, CA 95132 (77-0556796)	<u>\$ (35,855)</u>	<u>\$ 16,382</u>
52%	Suspended Animation, Inc 1082 S Rodgers Circle Boca Raton, FL 33487 (46-0466303)	<u>\$ (322,334)</u>	<u>\$ 419,011</u>

All of the following entities are in the research and development business

NOTE L – SCHEDULE A – PART IV

Life Extension Foundation, Inc. was inactive for years prior to 1997. The minutes from a Board Meeting held on October 30, 1996, state the following

A review of the financial records indicated that all present and former directors served as unpaid volunteers, and that the organization had remained virtually inactive from the years 1977 to 1996

Although the organization was not receiving public support and did not have any source of support during the years prior to 1997, due to the “unused grant” and donation of tangible and intangible assets from Life Extension Society, Inc., the public support for 1997 was approximately 79%, using 1997 figures. The gross investment percentage was approximately 16%. Both figures place Life Extension Foundation, Inc. squarely within the requirements for public support as set forth in Section 509(a)(1) or Section 509(a)(2)

NOTE M – SCHEDULE A – PART VI-B

Life Extension Foundation Buyers Club (“Buyers Club”), a for-profit corporation funds and publishes the Life Extension Magazine and distributes the magazine to all Life Extension Foundation members. This magazine serves as a means of describing the vitamin supplement products that Buyers Club sells to the public, in addition to the informative articles that are carefully researched and presented in the Magazine that are of interest to the Foundation’s members. Occasionally, the Magazine publishes articles highlighting legislation that affects the interests of the Foundation members. However, the Magazine is fully funded by Buyers Club. There are no lobbying expenditures funded by the Foundation.

# Application for Extension of Time To File an Exempt Organization Return

File a separate application for each return.

- If you are filing for an Automatic 3-Month Extension, complete only Part I and check this box
- If you are filing for an Additional (not automatic) 3-Month Extension, complete only Part II (on page 2 of this form)

Note: Do not complete Part II unless you have already been granted an automatic 3-month extension on a previously filed Form 8868.

## Part I Automatic 3-Month Extension of Time — Only submit original (no copies needed)

Note: Form 990-T corporations requesting an automatic 6-month extension — check this box and complete Part I only

All other corporations (including Form 990-C filers) must use Form 7004 to request an extension of time to file income tax returns. Partnerships, REMICs and trusts must use Form 8736 to request an extension of time to file Form 1065, 1066, or 1041

Type or print	Name of Exempt Organization	Employer Identification number
File by the due date for filing your return See instructions	LIFE EXTENSION FOUNDATION, INC C/O BERNARD SINGER, ESQ 3107 STIRLING RD FT LAUDERDALE, FL 33312	59-1746396
	Instructions	
	Physical address, see instructions	

Check type of return to be filed (file a separate application for each return)

- |  |  |                                    |
|--|--|------------------------------------|
| <input checked="" type="checkbox"/> Form 990 | <input type="checkbox"/> Form 990-T (corporation)                | <input type="checkbox"/> Form 4720 |
| <input type="checkbox"/> Form 990-BL         | <input type="checkbox"/> Form 990-T (sec 401(a) or 408(a) trust) | <input type="checkbox"/> Form 5227 |
| <input type="checkbox"/> Form 990-EZ         | <input type="checkbox"/> Form 990-T (trust other than above)     | <input type="checkbox"/> Form 6069 |
| <input type="checkbox"/> Form 990-PF         | <input type="checkbox"/> Form 1041-A                             | <input type="checkbox"/> Form 8870 |

- If the organization does not have an office or place of business in the United States, check this box
- If this is for a Group Return, enter the organization's four digit Group Exemption Number (GEN) \_\_\_\_\_ If this is for the whole group, check this box  If it is for part of the group, check this box  and attach a list with the names and EINs of all members the extension will cover

1 I request an automatic 3-month (6-month, for 990-T corporation) extension of time until \_\_\_\_\_, 20\_\_\_\_, to file the exempt organization return for the organization named above. The extension is for the organization's return for

▶  calendar year 20\_\_\_\_ or

▶  tax year beginning \_\_\_\_\_, 20\_\_\_\_, and ending \_\_\_\_\_, 20\_\_\_\_

2 If this tax year is for less than 12 months, check reason  Initial return  Final return  Change in accounting period

3a If this application is for Form 990-BL, 990-PF, 990-T, 4720, or 6069, enter the tentative tax, less any nonrefundable credits. See instructions \$ \_\_\_\_\_

b If this application is for Form 990-PF or 990-T, enter any refundable credits and estimated tax payments made. Include any prior year overpayment allowed as a credit \$ \_\_\_\_\_

c Balance Due Subtract line 3b from line 3a. Include your payment with this form, or, if required, deposit with FTD coupon or, if required, by using EFTPS (Electronic Federal Tax Payment System). See instructions \$ \_\_\_\_\_

### Signature and Verification

Under penalties of perjury I declare that I have examined this form including accompanying schedules and statements, and to the best of my knowledge and belief it is true correct, and complete and that I am authorized to prepare this form

Signature \_\_\_\_\_ Title \_\_\_\_\_ Date \_\_\_\_\_

For Paperwork Reduction Act Notice, see Instruction



• If you are filing for an Additional (not automatic) 3-Month Extension, complete only Part II and check this box  . . . . .

Note: Only complete Part II if you have already been granted an automatic 3-month extension on a previously filed Form 8868.

• If you are filing for an Automatic 3-Month Extension, complete only Part I (on page 1)

**Part II Additional (not automatic) 3-Month Extension of Time — Must File Original and One Copy.**

Type or print	Name of Exempt Organization	Employer identification number
File by the extended due date for filing the return See instructions	LIFE EXTENSION FOUNDATION, INC., C/O BERNARD SINGER, ESQ 3167 STIRLING RD FT. LAUDERDALE, FL 33312	59-1746396 For IRS use only
	Instructions	
	Sign address, see instructions	

Check type of return to be filed (File a separate application for each return)

- Form 990     Form 990-EZ     Form 990-T (sec 401(a) or 408(a) trust)     Form 1041-A     Form 5227     Form 8870  
 Form 990-BL     Form 990-PF     Form 990-T (trust other than above)     Form 4720     Form 6069

**STOP: Do not complete Part II if you were not already granted an automatic 3-month extension on a previously filed Form 8868.**

• If the organization does not have an office or place of business in the United States, check this box  . . . . .

• If this is for a Group Return, enter the organization's four digit Group Exemption Number (GEN) \_\_\_\_\_ If this is for the whole group, check this box  If it is for part of the group, check this box  and attach a list with the names and EINs of all members the extension is for

- 4 I request an additional 3-month extension of time until NOV 15, 2003  
 5 For calendar year 2002, or other tax year beginning \_\_\_\_\_, 20\_\_\_\_ and ending \_\_\_\_\_, 20\_\_\_\_  
 6 If this tax year is for less than 12 months, check reason  Initial return  Final return  Change in accounting period  
 7 State in detail why you need the extension Not all information needed to file a complete return has been received.

- 8a If this application is for Form 990-BL, 990-PF, 990-T, 4720, or 6069, enter the tentative tax, less any nonrefundable credits See instructions \$ \_\_\_\_\_  
 b If this application is for Form 990-PF, 990-T, 4720, or 6069, enter any refundable credits and estimated tax payments made Include any prior year overpayment allowed as a credit and any amount paid previously with Form 8868 \$ \_\_\_\_\_  
 c Balance Due. Subtract line 8b from line 8a Include your payment with this form, or, if required, deposit with FTD coupon or, if required, by using EFTPS (Electronic Federal Tax Payment System) See instructions \$ \_\_\_\_\_

**Signature and Verification**

Under penalties of perjury I declare that I have examined this form including accompanying schedules and statements and to the best of my knowledge and belief it is true correct, and complete and that I am authorized to prepare this form

Signature ▶ \_\_\_\_\_

Title ▶ C.P.A.

Date ▶ 8/14/03

**Notice to Applicant — To Be Completed by the IRS**

- We have approved this application Please attach this form to the organization's return  
 We have not approved this application However, we have granted a 10-day grace period from the later of the date shown below or the due date of the organization's return (including any prior extensions) This grace period is considered to be a valid extension of time for elections otherwise required to be made on a timely return Please attach this form to the organization's return  
 We have not approved this application After considering the reasons stated in item 7, we cannot grant your request for an extension of time to file We are not granting a 10-day grace period  
 We cannot consider this application because it was filed after the due date of the return for which an extension was requested  
 Other \_\_\_\_\_

Director \_\_\_\_\_

By \_\_\_\_\_

Date \_\_\_\_\_

Alternate Mailing Address — Enter the address if you want the copy of this application for an additional 3-month extension returned to an address different than the one entered above

Type or print	Name
	LIFE EXTENSION FOUNDATION, INC.,
	Number and street (include suite, room, or apt no) Or a PO box number
	c/o BURTON & CO. P.A., CPA
	City or town, province or state, and country (including postal or ZIP code)
	HOLLYWOOD, FLORIDA 33021